Bill.com Holdings Inc vs Zoetis Inc — how do they compare? Bill.com Holdings Inc trades at $44.17 (market cap $4.12B), while Zoetis Inc trades at $74.68 (market cap $31.05B). The key difference: Zoetis Inc is far larger — about 7.5× Bill.com Holdings Inc's market cap, and Zoetis Inc pays a 2.86% dividend while Bill.com Holdings Inc pays none. Which is the better fit depends on your goals.
| BILL | ZTS | |
|---|---|---|
Market Cap | $4.12B | $31.05B |
Sector | Technology | Health |
52-Week High | $56.32 | $156.76 |
52-Week Low | $31.96 | $71.91 |
Enterprise Value | $3.83B | $38.35B |
Dividend Yield | — | 2.86% |
Signals from Pluang's Aura AI — not financial advice
BILL Holdings trades at $42.86, up 3.63% today, with strong technical momentum and bullish analyst sentiment. The stock has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $0.68 surpassing the $0.55 estimate. Revenue growth is robust, rising from $642M in 2022 to $1.46B in 2025, though net margins remain thin at 0.01%. Recent leadership changes and a $1B buyback program signal strategic focus on growth and shareholder value.
Outlook is positive with a consensus price target of $48.00 implying 12% upside, supported by 56% analyst buy ratings. Key risks include high valuation multiples (P/E 213.91), competitive pressures in SaaS, and sensitivity to small business economic health. Cash flow trends show operational improvement, but investing outflows remain elevated.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Bill.com Holdings Inc is a provider of cloud-based software that simplifies, digitizes, and automates financial operations for SMBs. Its artificial-intelligence enabled financial software platform used mostly to build connections between customers, suppliers, and clients. The company's platform generates and process invoices, streamline approvals, send and receive payments, sync with their accounting system, and manage their cash. The firm generates revenue through subscription and transaction fees.
Read more on BILL →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →